Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2023

Open Access 01-12-2023 | Bronchiectasis | Research

The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO

Authors: Robert A. Stockley, Anita Pye, Joshua De Soyza, Alice M. Turner, Marc Miravitlles, the EARCO study investigators

Published in: Orphanet Journal of Rare Diseases | Issue 1/2023

Login to get access

Abstract

Background

Although bronchiectasis has been recognised as a feature of some patients with Alpha1-Antitrypsin deficiency the prevalence and characteristics are not widely known. We wished to determine the prevalence of bronchiectasis and patient characteristics. The first cohort of patients recruited to the EARCO (European Alpha1 Research Collaboration) International Registry data base by the end of 2021 was analysed for radiological evidence of both emphysema and bronchiectasis as well as baseline demographic features.

Results

Of the first 505 patients with the PiZZ genotype entered into the data base 418 (82.8%) had a reported CT scan. There were 77 (18.4%) with a normal scan and 38 (9.1%) with bronchiectasis alone. These 2 groups were predominantly female never smokers and had lung function in the normal range. The remaining 303 (72.5%) ZZ patients all had emphysema on the scan and 113 (27%) had additional evidence of bronchiectasis.

Conclusions

The data indicates the bronchiectasis alone is a feature of 9.1% of patients with the PiZZ genotype of Alpha1-antitrypsin deficiency but although emphysema is the dominant lung pathology bronchiectasis is also present in 27% of emphysema cases and may require a different treatment strategy.
Literature
1.
go back to reference Stockley RA. α1-antitrypsin: a polyfunctional protein? Lancet Resp Med. 2015;3(5):341–3.CrossRef Stockley RA. α1-antitrypsin: a polyfunctional protein? Lancet Resp Med. 2015;3(5):341–3.CrossRef
2.
go back to reference Crisford H, Sapey E, Stockley RA. Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory disease. Respir Res. 2018;19:180.CrossRefPubMedPubMedCentral Crisford H, Sapey E, Stockley RA. Proteinase 3; a potential target in chronic obstructive pulmonary disease and other chronic inflammatory disease. Respir Res. 2018;19:180.CrossRefPubMedPubMedCentral
3.
go back to reference Eriksson S. Pulmonary emphysema and alpha-1 antitrypsin deficiency. Acta Med Scand. 1964;175:197–205.CrossRefPubMed Eriksson S. Pulmonary emphysema and alpha-1 antitrypsin deficiency. Acta Med Scand. 1964;175:197–205.CrossRefPubMed
4.
go back to reference Guest PJ, Hansell DM. High resolution computed tomography (HRCT) in emphysema associated with a1-antitrypsin deficiency. Clin Radiol. 1992;45:260–6.CrossRefPubMed Guest PJ, Hansell DM. High resolution computed tomography (HRCT) in emphysema associated with a1-antitrypsin deficiency. Clin Radiol. 1992;45:260–6.CrossRefPubMed
5.
go back to reference Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007;15(12):1215–21.CrossRef Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007;15(12):1215–21.CrossRef
6.
go back to reference Eden E, Choate R, Barker A, Addrizzo-Harris D, Aksamit TR, Daley CL, Daniles MLA, DiMaggio A, Fennelly K, Griffith DE, Johnson MM, Knowles MR, Metersky ML, Noone PG, O’Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Turino GM, Winthrop KL. The clinical features of bronchiectasis associated with alpha-1 antitrypsin deficiency, common variable immunodeficiency and primary ciliary dyskinesia – results from the U.S. Bronchiectasis Research Registry. Chronic Obstr Pulm Dis. 2019;6:145–53.PubMedPubMedCentral Eden E, Choate R, Barker A, Addrizzo-Harris D, Aksamit TR, Daley CL, Daniles MLA, DiMaggio A, Fennelly K, Griffith DE, Johnson MM, Knowles MR, Metersky ML, Noone PG, O’Donnell AE, Olivier KN, Salathe MA, Schmid A, Thomashow B, Tino G, Turino GM, Winthrop KL. The clinical features of bronchiectasis associated with alpha-1 antitrypsin deficiency, common variable immunodeficiency and primary ciliary dyskinesia – results from the U.S. Bronchiectasis Research Registry. Chronic Obstr Pulm Dis. 2019;6:145–53.PubMedPubMedCentral
7.
go back to reference Cuvelier A, Muir JF, Hellot MF, Benhamou D, Martin JP, Benichou J, Sesboue R. Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest. 2000;117:415–9.CrossRefPubMed Cuvelier A, Muir JF, Hellot MF, Benhamou D, Martin JP, Benichou J, Sesboue R. Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest. 2000;117:415–9.CrossRefPubMed
8.
go back to reference Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, Polverino E, Van de kerkhove C, Rutherford R, Davison J, Rosales E, Pesci A, Restrepo MI, Torres A, Aliberti S. Etiology of non–cystic fibrosis bronchiectasis in adults and its correlation to Disease Severity. Ann Am Thorac Soc. 2015;12(12):1764–70.CrossRefPubMedPubMedCentral Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, Polverino E, Van de kerkhove C, Rutherford R, Davison J, Rosales E, Pesci A, Restrepo MI, Torres A, Aliberti S. Etiology of non–cystic fibrosis bronchiectasis in adults and its correlation to Disease Severity. Ann Am Thorac Soc. 2015;12(12):1764–70.CrossRefPubMedPubMedCentral
9.
go back to reference Hill AT, Campbell EJ, Hill SL, Bayley D, Stockley RA. Association between airway bacterial load and markers of inflammation in patients with stable chronic bronchitis. Am J Med. 2000;109:288–95.CrossRefPubMed Hill AT, Campbell EJ, Hill SL, Bayley D, Stockley RA. Association between airway bacterial load and markers of inflammation in patients with stable chronic bronchitis. Am J Med. 2000;109:288–95.CrossRefPubMed
10.
go back to reference Cooke JC, Currie DC, Morgan AD, Kerr IH, Delany D, Strickland B, Cole PJ. Role of computed tomography in diagnosis of bronchiectasis. Thorax. Apr; 1987;42(4):272–7.CrossRefPubMedPubMedCentral Cooke JC, Currie DC, Morgan AD, Kerr IH, Delany D, Strickland B, Cole PJ. Role of computed tomography in diagnosis of bronchiectasis. Thorax. Apr; 1987;42(4):272–7.CrossRefPubMedPubMedCentral
11.
go back to reference Whitters D, Stockley RA. Immunity and bacterial colonization in bronchiectasis. Thorax. 2012;67:1006–13.CrossRefPubMed Whitters D, Stockley RA. Immunity and bacterial colonization in bronchiectasis. Thorax. 2012;67:1006–13.CrossRefPubMed
12.
go back to reference Stockley RA. Bronchiectasis. Medicine. 1999;27(10):113–6. Stockley RA. Bronchiectasis. Medicine. 1999;27(10):113–6.
13.
go back to reference Hill AT, Bayley DL, Campbell EJ, Hill SL, Stockley RA. Airways inflammation in chronic bronchitis: the effects of smoking and α1-antitrypsin deficiency. Eur Respir J. 2000;15:886–90.CrossRefPubMed Hill AT, Bayley DL, Campbell EJ, Hill SL, Stockley RA. Airways inflammation in chronic bronchitis: the effects of smoking and α1-antitrypsin deficiency. Eur Respir J. 2000;15:886–90.CrossRefPubMed
14.
go back to reference Stockley RA, Bayley DL, Unsal I, Dowson L. The effect of augmentation therapy on bronchial inflammation in α1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165:1494–8.CrossRefPubMed Stockley RA, Bayley DL, Unsal I, Dowson L. The effect of augmentation therapy on bronchial inflammation in α1-antitrypsin deficiency. Am J Respir Crit Care Med. 2002;165:1494–8.CrossRefPubMed
15.
go back to reference Carreto L, Morrison M, Donovan J, Finch S, Tan GL, Fardon T, Wilson R, Furrie E, Loebinger M, Chalmers JD. Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis. Thorax. 2020;75(7):592–3.CrossRefPubMed Carreto L, Morrison M, Donovan J, Finch S, Tan GL, Fardon T, Wilson R, Furrie E, Loebinger M, Chalmers JD. Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis. Thorax. 2020;75(7):592–3.CrossRefPubMed
17.
go back to reference De Serres FJ, Blanco I. Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;6(5):277–95.CrossRefPubMed De Serres FJ, Blanco I. Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012;6(5):277–95.CrossRefPubMed
18.
go back to reference Miravitlles M, Turner AM, Torres-Duran M, Tanash H, Rodríguez-García C, López-Campos JL, Chlumsky J, Guimaraes C, Rodríguez-Hermosa JL, Corsico A, Martinez-González C, Hernández-Pérez JM, Bustamante A, Parr DG, Casas-Maldonado F, Hecimovic A, Janssens W, Lara B, Barrecheguren M, González C, Stolk J, Esquinas C, Clarenbach CF. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry. Respir Res. 2022;16(1):352.CrossRef Miravitlles M, Turner AM, Torres-Duran M, Tanash H, Rodríguez-García C, López-Campos JL, Chlumsky J, Guimaraes C, Rodríguez-Hermosa JL, Corsico A, Martinez-González C, Hernández-Pérez JM, Bustamante A, Parr DG, Casas-Maldonado F, Hecimovic A, Janssens W, Lara B, Barrecheguren M, González C, Stolk J, Esquinas C, Clarenbach CF. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry. Respir Res. 2022;16(1):352.CrossRef
19.
go back to reference Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohle MR, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex J-F, O’Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M, on behalf of the EARCO Clinical Research Collaboration. Protocol for the EARCO Registry: a pan-european observational study in patients with α1-antitrypsin deficiency. ERJ Open Res. 2020;6(1):00181–2019.CrossRefPubMedPubMedCentral Greulich T, Altraja A, Barrecheguren M, Bals R, Chlumsky J, Chorostowska-Wynimko J, Clarenbach C, Corda L, Corsico AG, Ferrarotti I, Esquinas C, Gouder C, Hećimović A, Ilic A, Ivanov Y, Janciauskiene S, Janssens W, Kohle MR, Krams A, Lara B, Mahadeva R, McElvaney G, Mornex J-F, O’Hara K, Parr D, Piitulainen E, Schmid-Scherzer K, Seersholm N, Stockley RA, Stolk J, Sucena M, Tanash H, Turner A, Ulmeanu R, Wilkens M, Yorgancioğlu A, Zaharie A, Miravitlles M, on behalf of the EARCO Clinical Research Collaboration. Protocol for the EARCO Registry: a pan-european observational study in patients with α1-antitrypsin deficiency. ERJ Open Res. 2020;6(1):00181–2019.CrossRefPubMedPubMedCentral
20.
go back to reference Stolk J, Tov N, Chapman KR, Fernandez P, MacNee W, Hopkinson NS, Piitulainen E, Seersholm N, Vogelmeier CF, Bals R, McElvaney G, Stockley RA. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019;21(5):1900673.CrossRef Stolk J, Tov N, Chapman KR, Fernandez P, MacNee W, Hopkinson NS, Piitulainen E, Seersholm N, Vogelmeier CF, Bals R, McElvaney G, Stockley RA. Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD. Eur Respir J. 2019;21(5):1900673.CrossRef
21.
go back to reference Pye A, Turner AM. Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. Expert Opin Investig Drugs. 2019;28(10):891–902.CrossRefPubMed Pye A, Turner AM. Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. Expert Opin Investig Drugs. 2019;28(10):891–902.CrossRefPubMed
22.
go back to reference Whitters D, Stockley RA. Bronchiectasis in older patients with chronic obstructive pulmonary disease: prevalence, diagnosis and therapeutic management. Drugs Aging. 2013;30(4):215–25.CrossRefPubMed Whitters D, Stockley RA. Bronchiectasis in older patients with chronic obstructive pulmonary disease: prevalence, diagnosis and therapeutic management. Drugs Aging. 2013;30(4):215–25.CrossRefPubMed
23.
24.
go back to reference Naidich DP. High-resolution computed tomography of cystic lung disease. Semin Roentgenol. 1991;26:151–74.CrossRefPubMed Naidich DP. High-resolution computed tomography of cystic lung disease. Semin Roentgenol. 1991;26:151–74.CrossRefPubMed
25.
go back to reference Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(8):823–31.CrossRefPubMed Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(8):823–31.CrossRefPubMed
26.
go back to reference Patel IS, Vlahos I, Wilkinson TMA, Loyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. Aug 2004;15(4):400–7.CrossRef Patel IS, Vlahos I, Wilkinson TMA, Loyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. Aug 2004;15(4):400–7.CrossRef
27.
go back to reference Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O’Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, Daley CL, WILLOW Investigators. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383(22):2127–37.CrossRefPubMed Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O’Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, Daley CL, WILLOW Investigators. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383(22):2127–37.CrossRefPubMed
28.
go back to reference Traversi L, Miravitlles M, Martinez-Garcia MA, et al. ROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Res. 2021;7:00399–2021.CrossRefPubMedPubMedCentral Traversi L, Miravitlles M, Martinez-Garcia MA, et al. ROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Res. 2021;7:00399–2021.CrossRefPubMedPubMedCentral
29.
go back to reference Franciosi AN, Hobbs BD, McElvaney OJ, Molloy K, Hersh C, Clarke L, Gunaratnam C, Silverman EK, Carroll TP, McElvaney NG. Clarifying the risk of lung disease in SZ alpha1 antitrypsin deficiency. Am J Respir Crit Care Med. 2020;202(1):73–82.CrossRefPubMedPubMedCentral Franciosi AN, Hobbs BD, McElvaney OJ, Molloy K, Hersh C, Clarke L, Gunaratnam C, Silverman EK, Carroll TP, McElvaney NG. Clarifying the risk of lung disease in SZ alpha1 antitrypsin deficiency. Am J Respir Crit Care Med. 2020;202(1):73–82.CrossRefPubMedPubMedCentral
Metadata
Title
The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO
Authors
Robert A. Stockley
Anita Pye
Joshua De Soyza
Alice M. Turner
Marc Miravitlles
the EARCO study investigators
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2023
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-023-02830-2

Other articles of this Issue 1/2023

Orphanet Journal of Rare Diseases 1/2023 Go to the issue